SlideShare a Scribd company logo
A
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Associação Hospitalar Moinhos de Vento, Porto Alegre, Brazil.
Funding: CNPq, FAPERGS, FIPE/HCPA CAPES, Susan G. Komen for the Cure.
BACKGROUNDBACKGROUND
Nowadays, breast cancer (BC) is the most prevalent type of cancer among women.
Specifically in Brazil, BC is a public health issue due to its morbidity and high incidence
and mortality rates. Mathematical models were developed to predict a woman’s lifetime
risk for BC considering her family history (FH) and personal risk factors for breast cancer
(PF). Between these models, the Gail and Tyrer-Cuzick models and the Claus tables are
the most used. There are no references to application of these risk models in a large
sample from Brazil.
OBJECTIVESOBJECTIVES
 To describe the risk estimatives, according the three different models, in a sample of
women undergoing mammographic screening in Sothern Brazil, a geographic area with
high breast cancer incidence and mortality rates.
 To find correlations between the risk estimatives derived from the models in the sample.
SCHMIDT AV, GIACOMAZZI J, ASHTON-PROLLA P, CAMEY SA,SCHMIDT AV, GIACOMAZZI J, ASHTON-PROLLA P, CAMEY SA, CALLEFI MCALLEFI M
METHODOLOGYMETHODOLOGY
Study Participants: We used data from women in the population-based cohort study
NMPOA (n=9218), which represents a large sample from an underserved community in
southern Brazil. For this study, a sample of 1795 women was analysed, 885 of whom
answered positively to at least one of seven questions about FH of breast, ovarian and
colorectal cancer. The remaining 910 participants answered negatively to all questions
on the presence of a positive family history for any of these tumors. Patients were
referred to genetic cancer risk assessment (GCRA) where interviews with clinical
geneticists and detailed pedigree analyses were performed. Ethical approval was
obtained from the institutional ethics committees and patient inclusion required
signature of informed consent.
Statistical Analysis: To characterize the models, the average and the respective
confidence intervals of 95% were used. To obtain the population mean and prevalence
data we used weight estimation, weighting the group with (1285/885) and without
(7933/910) positive family history. The Pearson’s Correlation Coefficient was used to
verify the existence of correlation between models.
Table 1: Variables used in each BC prediction model
Variable Gail Claus Tyrer-Cuzick
Personal Information
Age
BMI
Reproductive History
Menarche
Age at firsl live-birth
Menopause
Breast Disease
Breast biopsy
Atypical hyperplasia
Ductal carcinoma in situ
Family History of BC
1st
degree
2nd
degree
Age at diagnosis
BC in relatives
Ovarian Cancer
Based on Lalloo et al. 2005  
RESULTSRESULTS
All women included in the study were cancer unaffected. Average age at risk
estimation was 47.24 years (minimum = 17, maximum = 84, SD =11.67). The number of
women who confirmed FH in the GRCA interview was 800. The number of valid cases to
estimate risk by each model was 1755, 635 and 1750 for Gail, Claus and Tyrer-Cuzick
models, respectively.
For the entire sample, the following correlation values were encountered: between the
Claus tables and the Tyrer-Cuzick model (0.44, p<0.01), between the Gail and Tyrer-
Cuzick models (0.69, p<0.01) and between the Claus tables and the Gail model (0.40,
p<0.01). Table 2 represents these correlations for both groups, with and without family
history. Averages and confidence intervals (CI95%) of the estimated risk of developing
breast cancer according to the Gail and Tyrer-Cuzick models and the Claus tables are
shown in table 3.
Considering the average estimated lifetime breast cancer risk in Brazilian women of
10% and using this value as cutoff for each model, 1882 (20.1%), 1616 (17.5%) and
1390 (17.8%) of the women studied had lifetime risk estimates above 10% using the Gail
Model, Claus tables and the Tyrer-Cuzick model, respectively.
Table 2 : Correlations between the models
DISCUSSIONDISCUSSION
Overall, the average estimated lifetime risk of developing breast cancer in this sample of
cancer-unaffected women from an underserved community in Southern Brazil was within the
expected interval for average risk women of the general population in this country. As expexted,,
mean risk estimates were higher in women with a family history of the disease, using all three
models. In addition, we observed a correlation between the risks given by the three models;
additional analyses are necessary to determine which one fits better to the study’s community.
The highest correlation was observed between the Gail and Tyrer-Cuzick models, and this is
likely explained by their general similar structure and high number of common variables, which
are possibly more expressive in the sample than the main variables (family history) used by the
Claus Tables.
OBS: The values of the superior and inferior diagonals represent the correlations in the group with
and without family history, respectively.
Table 3 : Mean risk estimates and confidence intervals
for each model
Gail Claus Tyrer-Cuzick
Gail - 0.184 (p=0.96) 0.637 (p<0.01)
Claus 0.369 (p<0.01) - 0.281 (p<0.01)
Tyrer-Cuzick 0.599 (p<0.01) 0.43 (p<0.01) -
Mean CI95%
Gail
All women 8.14 8.07-8.21
With FH 11.57 11.28-11.87
Without FH 7.53 7.48-7.59
Claus
All women 8.91 8.85-8.98
With FH 11.88 11.59-12.17
Without FH 8.39 8.34-8.44
Tyrer-Cuzick
All women 7.02 6.94-7.09
With FH 11.26 10.99-11.53
Without FH 6.26 6.20-6.33
  






 










Correlation between Claus Tables, and Gail and Tyrer-Correlation between Claus Tables, and Gail and Tyrer-
Cuzick models in a population-based cohort studyCuzick models in a population-based cohort study
Contact: aishameriane.schmidt@ufrgs.br


More Related Content

What's hot

A data driven nomogram for breast cancer survival
A data driven nomogram for breast cancer survivalA data driven nomogram for breast cancer survival
A data driven nomogram for breast cancer survival
Lisa Federer
 
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
UCLA
 
Senology Newsletter - July 3, 2013
Senology Newsletter - July 3, 2013Senology Newsletter - July 3, 2013
Senology Newsletter - July 3, 2013
Senology.org
 
Senology Newsletter - February 7, 2013
Senology Newsletter - February 7, 2013Senology Newsletter - February 7, 2013
Senology Newsletter - February 7, 2013
Senology.org
 
Biol 3095 – 2012 Annotated bibliographies
Biol 3095 – 2012 Annotated bibliographiesBiol 3095 – 2012 Annotated bibliographies
Biol 3095 – 2012 Annotated bibliographiesCarla-Figueroa-Garcia
 
Senology.org Newsletter - November 3, 2011
Senology.org Newsletter - November 3, 2011Senology.org Newsletter - November 3, 2011
Senology.org Newsletter - November 3, 2011
Senology.org
 
Evaluating cancer in twins
Evaluating cancer in twinsEvaluating cancer in twins
Evaluating cancer in twins
Gil Lederman
 

What's hot (7)

A data driven nomogram for breast cancer survival
A data driven nomogram for breast cancer survivalA data driven nomogram for breast cancer survival
A data driven nomogram for breast cancer survival
 
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...
 
Senology Newsletter - July 3, 2013
Senology Newsletter - July 3, 2013Senology Newsletter - July 3, 2013
Senology Newsletter - July 3, 2013
 
Senology Newsletter - February 7, 2013
Senology Newsletter - February 7, 2013Senology Newsletter - February 7, 2013
Senology Newsletter - February 7, 2013
 
Biol 3095 – 2012 Annotated bibliographies
Biol 3095 – 2012 Annotated bibliographiesBiol 3095 – 2012 Annotated bibliographies
Biol 3095 – 2012 Annotated bibliographies
 
Senology.org Newsletter - November 3, 2011
Senology.org Newsletter - November 3, 2011Senology.org Newsletter - November 3, 2011
Senology.org Newsletter - November 3, 2011
 
Evaluating cancer in twins
Evaluating cancer in twinsEvaluating cancer in twins
Evaluating cancer in twins
 

Similar to Correlação entre modelos de Risco para CA de MAMA

Why are Breast Cancers More Aggressive in Black Women?
Why are Breast Cancers More Aggressive in Black Women?Why are Breast Cancers More Aggressive in Black Women?
Why are Breast Cancers More Aggressive in Black Women?
bkling
 
Breast_cancer_risk_factors_survival_and_recurrence-1.pdf
Breast_cancer_risk_factors_survival_and_recurrence-1.pdfBreast_cancer_risk_factors_survival_and_recurrence-1.pdf
Breast_cancer_risk_factors_survival_and_recurrence-1.pdf
Yelmi Reni Putri SY
 
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
Premier Publishers
 
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
UCLA
 
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
alamocitycancercouncil
 
1
11
Risk Appraisal Forum 2009 Westman
Risk Appraisal Forum 2009  WestmanRisk Appraisal Forum 2009  Westman
Risk Appraisal Forum 2009 Westmanfondas vakalis
 
Aggressive Breast Cancers in Black Women
Aggressive Breast Cancers in Black WomenAggressive Breast Cancers in Black Women
Aggressive Breast Cancers in Black Women
bkling
 
Evidence based management options for women at increased breast diseases
Evidence based management options for women at increased breast diseases Evidence based management options for women at increased breast diseases
Evidence based management options for women at increased breast diseases
Kawita Bapat
 
Breast cancer survival and race
Breast cancer survival and raceBreast cancer survival and race
Breast cancer survival and race
Madhav Kc
 
Breast cancer 2021
Breast cancer 2021Breast cancer 2021
Breast cancer 2021
Robert J Miller MD
 
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
Holly Giovi, RN
 
RSNA: van Colen: Breast Density
RSNA: van Colen: Breast DensityRSNA: van Colen: Breast Density
RSNA: van Colen: Breast DensityTriMed Media Group
 
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
DrHeena tiwari
 
SAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdfSAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdf
ssuser82d3bb
 
11.relationship between the levels of serum thyroid hormones and the risk of ...
11.relationship between the levels of serum thyroid hormones and the risk of ...11.relationship between the levels of serum thyroid hormones and the risk of ...
11.relationship between the levels of serum thyroid hormones and the risk of ...Alexander Decker
 
Leche y cancer
Leche y cancerLeche y cancer
Leche y cancer
renemendez9
 
Knowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer DatabaseKnowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer Database
iosrjce
 
Am. j. epidemiol. 2016-robinson-388-99
Am. j. epidemiol. 2016-robinson-388-99Am. j. epidemiol. 2016-robinson-388-99
Am. j. epidemiol. 2016-robinson-388-99
Esposito Evelyn
 

Similar to Correlação entre modelos de Risco para CA de MAMA (20)

Why are Breast Cancers More Aggressive in Black Women?
Why are Breast Cancers More Aggressive in Black Women?Why are Breast Cancers More Aggressive in Black Women?
Why are Breast Cancers More Aggressive in Black Women?
 
Breast_cancer_risk_factors_survival_and_recurrence-1.pdf
Breast_cancer_risk_factors_survival_and_recurrence-1.pdfBreast_cancer_risk_factors_survival_and_recurrence-1.pdf
Breast_cancer_risk_factors_survival_and_recurrence-1.pdf
 
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
Survival Analysis of Determinants of Breast Cancer Patients at Hossana Queen ...
 
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast ...
 
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
Breast Density, Breast Cancer Risk, and California Breast Density Notificatio...
 
1
11
1
 
Risk Appraisal Forum 2009 Westman
Risk Appraisal Forum 2009  WestmanRisk Appraisal Forum 2009  Westman
Risk Appraisal Forum 2009 Westman
 
Aggressive Breast Cancers in Black Women
Aggressive Breast Cancers in Black WomenAggressive Breast Cancers in Black Women
Aggressive Breast Cancers in Black Women
 
Evidence based management options for women at increased breast diseases
Evidence based management options for women at increased breast diseases Evidence based management options for women at increased breast diseases
Evidence based management options for women at increased breast diseases
 
Breast cancer survival and race
Breast cancer survival and raceBreast cancer survival and race
Breast cancer survival and race
 
Breast cancer 2021
Breast cancer 2021Breast cancer 2021
Breast cancer 2021
 
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
Slide Deck M4 001, 3 2010 P2 P Final Ppt 3.10
 
RSNA: van Colen: Breast Density
RSNA: van Colen: Breast DensityRSNA: van Colen: Breast Density
RSNA: van Colen: Breast Density
 
Van colen breast density 2
Van colen   breast density 2Van colen   breast density 2
Van colen breast density 2
 
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
EVALUATION OF BREAST CANCER AND ITS RELATION WITH PERIODONTAL DISEASES: AN OR...
 
SAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdfSAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdf
 
11.relationship between the levels of serum thyroid hormones and the risk of ...
11.relationship between the levels of serum thyroid hormones and the risk of ...11.relationship between the levels of serum thyroid hormones and the risk of ...
11.relationship between the levels of serum thyroid hormones and the risk of ...
 
Leche y cancer
Leche y cancerLeche y cancer
Leche y cancer
 
Knowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer DatabaseKnowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer Database
 
Am. j. epidemiol. 2016-robinson-388-99
Am. j. epidemiol. 2016-robinson-388-99Am. j. epidemiol. 2016-robinson-388-99
Am. j. epidemiol. 2016-robinson-388-99
 

More from Aishameriane Schmidt

Poster XX Salão de Iniciação Científica UFRGS
Poster XX Salão de Iniciação Científica UFRGSPoster XX Salão de Iniciação Científica UFRGS
Poster XX Salão de Iniciação Científica UFRGS
Aishameriane Schmidt
 
Pôster Congresso Brasileiro de Genética Médica 2008
Pôster Congresso Brasileiro de Genética Médica 2008Pôster Congresso Brasileiro de Genética Médica 2008
Pôster Congresso Brasileiro de Genética Médica 2008
Aishameriane Schmidt
 
Pôster salão de iniciação científica da UFRGS 2008
Pôster salão de iniciação científica da UFRGS 2008Pôster salão de iniciação científica da UFRGS 2008
Pôster salão de iniciação científica da UFRGS 2008
Aishameriane Schmidt
 
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto AlegrePôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Aishameriane Schmidt
 
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto AlegrePôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Aishameriane Schmidt
 
Processos k-factor GARMA
Processos k-factor GARMAProcessos k-factor GARMA
Processos k-factor GARMA
Aishameriane Schmidt
 
Geração e Estimação de processos k-factor GARMA
Geração e Estimação de processos k-factor GARMAGeração e Estimação de processos k-factor GARMA
Geração e Estimação de processos k-factor GARMA
Aishameriane Schmidt
 
Informações equivocadas sobre CA de Mama
Informações equivocadas sobre CA de MamaInformações equivocadas sobre CA de Mama
Informações equivocadas sobre CA de Mama
Aishameriane Schmidt
 
Conhecimento sobre CA de mama hereditário
Conhecimento sobre CA de mama hereditárioConhecimento sobre CA de mama hereditário
Conhecimento sobre CA de mama hereditário
Aishameriane Schmidt
 

More from Aishameriane Schmidt (9)

Poster XX Salão de Iniciação Científica UFRGS
Poster XX Salão de Iniciação Científica UFRGSPoster XX Salão de Iniciação Científica UFRGS
Poster XX Salão de Iniciação Científica UFRGS
 
Pôster Congresso Brasileiro de Genética Médica 2008
Pôster Congresso Brasileiro de Genética Médica 2008Pôster Congresso Brasileiro de Genética Médica 2008
Pôster Congresso Brasileiro de Genética Médica 2008
 
Pôster salão de iniciação científica da UFRGS 2008
Pôster salão de iniciação científica da UFRGS 2008Pôster salão de iniciação científica da UFRGS 2008
Pôster salão de iniciação científica da UFRGS 2008
 
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto AlegrePôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
 
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto AlegrePôster semana da Ciência do Hospital de Clínicas de Porto Alegre
Pôster semana da Ciência do Hospital de Clínicas de Porto Alegre
 
Processos k-factor GARMA
Processos k-factor GARMAProcessos k-factor GARMA
Processos k-factor GARMA
 
Geração e Estimação de processos k-factor GARMA
Geração e Estimação de processos k-factor GARMAGeração e Estimação de processos k-factor GARMA
Geração e Estimação de processos k-factor GARMA
 
Informações equivocadas sobre CA de Mama
Informações equivocadas sobre CA de MamaInformações equivocadas sobre CA de Mama
Informações equivocadas sobre CA de Mama
 
Conhecimento sobre CA de mama hereditário
Conhecimento sobre CA de mama hereditárioConhecimento sobre CA de mama hereditário
Conhecimento sobre CA de mama hereditário
 

Recently uploaded

Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBCSTRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
kimdan468
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
ArianaBusciglio
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 

Recently uploaded (20)

Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBCSTRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 

Correlação entre modelos de Risco para CA de MAMA

  • 1. A Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Associação Hospitalar Moinhos de Vento, Porto Alegre, Brazil. Funding: CNPq, FAPERGS, FIPE/HCPA CAPES, Susan G. Komen for the Cure. BACKGROUNDBACKGROUND Nowadays, breast cancer (BC) is the most prevalent type of cancer among women. Specifically in Brazil, BC is a public health issue due to its morbidity and high incidence and mortality rates. Mathematical models were developed to predict a woman’s lifetime risk for BC considering her family history (FH) and personal risk factors for breast cancer (PF). Between these models, the Gail and Tyrer-Cuzick models and the Claus tables are the most used. There are no references to application of these risk models in a large sample from Brazil. OBJECTIVESOBJECTIVES  To describe the risk estimatives, according the three different models, in a sample of women undergoing mammographic screening in Sothern Brazil, a geographic area with high breast cancer incidence and mortality rates.  To find correlations between the risk estimatives derived from the models in the sample. SCHMIDT AV, GIACOMAZZI J, ASHTON-PROLLA P, CAMEY SA,SCHMIDT AV, GIACOMAZZI J, ASHTON-PROLLA P, CAMEY SA, CALLEFI MCALLEFI M METHODOLOGYMETHODOLOGY Study Participants: We used data from women in the population-based cohort study NMPOA (n=9218), which represents a large sample from an underserved community in southern Brazil. For this study, a sample of 1795 women was analysed, 885 of whom answered positively to at least one of seven questions about FH of breast, ovarian and colorectal cancer. The remaining 910 participants answered negatively to all questions on the presence of a positive family history for any of these tumors. Patients were referred to genetic cancer risk assessment (GCRA) where interviews with clinical geneticists and detailed pedigree analyses were performed. Ethical approval was obtained from the institutional ethics committees and patient inclusion required signature of informed consent. Statistical Analysis: To characterize the models, the average and the respective confidence intervals of 95% were used. To obtain the population mean and prevalence data we used weight estimation, weighting the group with (1285/885) and without (7933/910) positive family history. The Pearson’s Correlation Coefficient was used to verify the existence of correlation between models. Table 1: Variables used in each BC prediction model Variable Gail Claus Tyrer-Cuzick Personal Information Age BMI Reproductive History Menarche Age at firsl live-birth Menopause Breast Disease Breast biopsy Atypical hyperplasia Ductal carcinoma in situ Family History of BC 1st degree 2nd degree Age at diagnosis BC in relatives Ovarian Cancer Based on Lalloo et al. 2005   RESULTSRESULTS All women included in the study were cancer unaffected. Average age at risk estimation was 47.24 years (minimum = 17, maximum = 84, SD =11.67). The number of women who confirmed FH in the GRCA interview was 800. The number of valid cases to estimate risk by each model was 1755, 635 and 1750 for Gail, Claus and Tyrer-Cuzick models, respectively. For the entire sample, the following correlation values were encountered: between the Claus tables and the Tyrer-Cuzick model (0.44, p<0.01), between the Gail and Tyrer- Cuzick models (0.69, p<0.01) and between the Claus tables and the Gail model (0.40, p<0.01). Table 2 represents these correlations for both groups, with and without family history. Averages and confidence intervals (CI95%) of the estimated risk of developing breast cancer according to the Gail and Tyrer-Cuzick models and the Claus tables are shown in table 3. Considering the average estimated lifetime breast cancer risk in Brazilian women of 10% and using this value as cutoff for each model, 1882 (20.1%), 1616 (17.5%) and 1390 (17.8%) of the women studied had lifetime risk estimates above 10% using the Gail Model, Claus tables and the Tyrer-Cuzick model, respectively. Table 2 : Correlations between the models DISCUSSIONDISCUSSION Overall, the average estimated lifetime risk of developing breast cancer in this sample of cancer-unaffected women from an underserved community in Southern Brazil was within the expected interval for average risk women of the general population in this country. As expexted,, mean risk estimates were higher in women with a family history of the disease, using all three models. In addition, we observed a correlation between the risks given by the three models; additional analyses are necessary to determine which one fits better to the study’s community. The highest correlation was observed between the Gail and Tyrer-Cuzick models, and this is likely explained by their general similar structure and high number of common variables, which are possibly more expressive in the sample than the main variables (family history) used by the Claus Tables. OBS: The values of the superior and inferior diagonals represent the correlations in the group with and without family history, respectively. Table 3 : Mean risk estimates and confidence intervals for each model Gail Claus Tyrer-Cuzick Gail - 0.184 (p=0.96) 0.637 (p<0.01) Claus 0.369 (p<0.01) - 0.281 (p<0.01) Tyrer-Cuzick 0.599 (p<0.01) 0.43 (p<0.01) - Mean CI95% Gail All women 8.14 8.07-8.21 With FH 11.57 11.28-11.87 Without FH 7.53 7.48-7.59 Claus All women 8.91 8.85-8.98 With FH 11.88 11.59-12.17 Without FH 8.39 8.34-8.44 Tyrer-Cuzick All women 7.02 6.94-7.09 With FH 11.26 10.99-11.53 Without FH 6.26 6.20-6.33                      Correlation between Claus Tables, and Gail and Tyrer-Correlation between Claus Tables, and Gail and Tyrer- Cuzick models in a population-based cohort studyCuzick models in a population-based cohort study Contact: aishameriane.schmidt@ufrgs.br 